Research Triangle Park, NC – Technology Commercialization Group, LLC (TCG), an international life science consulting firm specializing in interim management and strategic transaction services, is pleased to announce that Robert W. (Charlie) Turner has joined the firm as a new Partner.  Mr. Turner has over 25 years of senior-level business development, licensing and finance experience at Lilly, GSK, Novartis, Pappas Ventures, Pozen and Tri-Bio Ventures.  Over his career, Mr. Turner has played key roles in over 30 licensing, partnering and M&A transactions, with cumulative value exceeding $2.9 billion.  Most recently, he was President of Tri-Bio Ventures, LLC where he completed a dozen diverse biopharmaceutical transactions for his clients, including advisement for the April 2014 sale of Chatham Therapeutics, LLC to Baxter International inc. for $70 million upfront and undisclosed development, regulatory and commercial milestone payments.

“We are pleased to have Charlie join TCG because of his unique ‘hands-on’ experience in strategic transactions” commented Ken West, Managing Partner of TCG.  “With the increase in mergers and acquisitions in both the Pharmaceutical and Medical Device industries, more clients are seeking our help in executing strategic transactions. Charlie will make immediate contributions to this side of our business” Mr. West added.

“I am very excited to join the TCG team,” says Mr. Turner.  “I am impressed with my new Partners’ extensive experience in medical device, diagnostics, pharmaceutical and biotechnology markets and the successful interim management leadership and strategic transactions executed for our clients over the last 15 years.  I look forward to working as a part of the TCG team to continue building value for our pharmaceutical and biotechnology clients.”

As part of this growth, TCG has moved to new offices located in Raleigh, North Carolina near the Raleigh-Durham International Airport.